###### Strengths and limitations of this study

-   This meta-analysis pulls together the largest combined data set published to date from 21 studies representing self-reported health symptom data from over 129 000 Gulf War (GW)-deployed veterans and GW-era control veterans from four different countries, all branches of the military, and both Active Duty and Reserve components of the military.

-   The binomial-normal model used to calculate the summary estimates are specific to binary outcomes (eg, proportions and ORs).

-   Meta-analyses lack individual-level data; therefore, some covariates relevant to symptom reporting could not be assessed.

-   Non-reporting bias limits the comparison of primary studies with null or negative findings.

Introduction {#s1}
============

From 1990 to early 1991, approximately 700 000 troops from the USA, along with military personnel from over 30 coalition countries, were deployed to the Persian Gulf in support of Operation Desert Shield and Operation Desert Storm, collectively known as the Gulf War (GW).[@R1] After returning from the Persian Gulf, US GW veterans reported greater deployment-related health problems when compared with veterans of the same era who did not deploy to the Gulf or who were deployed elsewhere (eg, Bosnia, Germany).[@R2] Similar reports of increased ill health were seen in GW veterans from other countries, including the UK,[@R15] Australia,[@R20] Denmark,[@R21] Canada[@R22] and France.[@R23] Research indicates that US GW veterans developed certain chronic conditions at higher rates than their non-deployed counterparts (repeated seizures, neuralgia or neuritis, migraine headaches, and stroke) when assessed by self-report and where a representative sampling was verified by medical record reviews.[@R5] Higher rates of chronic diseases were also shown in longitudinal assessments of Australian GW veterans who had reported higher health symptoms on initial assessment when compared with their low symptom reporting counterparts.[@R26] In addition, about 25%--32% of deployed GW veterans reported symptoms from a common set of health complaints that have been used to construct criteria for a syndrome known as Gulf War illness (GWI).[@R1] These symptoms have remained chronic with no improvement over time.[@R10] GWI remains the primary chronic health disorder of GW deployment affecting over 200 000 deployed veterans.[@R1]

GWI is characterised in individual veterans by combinations of the following symptoms: chronic pain, fatigue, cognitive dysfunction, gastrointestinal complaints, respiratory symptoms and skin rashes, depending on the case definition employed and corresponding exclusion criteria.[@R1] Although there has been some controversy over whether GWI is a unique syndrome because of overlap of symptoms in affected and non-affected veterans,[@R3] this central group of symptoms has consistently been observed in investigations of USA, UK and Australian GW-deployed populations and has been used to determine case criteria for the illness.[@R1]

Two case definitions for GWI have received endorsement for use in clinical diagnosis and research investigations by the Institute of Medicine (IOM),[@R34] the Centers for Disease Control and Prevention (CDC), chronic multisymptom illness (CMI)[@R4] and the Kansas GWI definition.[@R13] According to the CDC CMI case definition, a veteran is diagnosed with GWI if she/he reports one or more symptoms that last for at least 6 months in two of three categories: fatigue, musculoskeletal pain and mood/cognition.[@R4] The Kansas definition requires moderate levels of self-reported symptoms in at least three out of six symptom categories: fatigue/sleep, pain, neurological/cognitive/mood, respiratory, gastrointestinal and skin.[@R13] A third set of symptoms used to define GWI are the Haley criteria.[@R36] These include three syndromes characterised by different symptom clusters. Syndrome 1 (impaired cognition) requires reported attention, memory, sleep and depression symptoms. Syndrome 2 (confusion/ataxia) requires reported thinking and balance symptoms. Syndrome 3 (neuropathic pain) requires self-reported joint and muscle pain.[@R36]

Uncertainty remains about the prevalence of GWI across GW-deployed populations because of differences in the study populations used to derive the case definitions and the methods used to ask about health symptoms. The Kansas definition is associated with a more consistent rate of GWI across multiple GW-deployed populations (34% prevalence in GW-deployed veterans) but excludes veterans with certain concomitant medical or psychiatric conditions who may also have GWI.[@R13] In contrast, depending on the population studied, the CDC case definition includes between 29% and 60% of GW veterans and is considered the most inclusive but the least specific of the case criteria.[@R34] Finally, the Haley criteria provide a more restrictive characterisation of GWI.[@R38] The syndromes were originally devised by assessing a specific military unit of US Navy Seabees who showed a 20% rate of GWI.[@R36] More current estimates in a larger population-based cohort showed that the combined Haley syndromes include about 14% of GW veterans.[@R6]

The epidemiological literature on health symptoms among GW veterans has identified environmental exposures unique to deployment to the Persian Gulf as aetiological agents in the development of specific health outcomes including brain cancer mortality and the occurrence of GWI.[@R1] Troops were often exposed to a complex mixture of chemical and physical hazards making it difficult to establish causal links between individual exposures and health outcomes. However, exposures that have been linked to health effects (eg, cognitive dysfunction, mood complaints and respiratory problems) in this veteran population include oil well fires,[@R33] pesticides,[@R10] pyridostigmine bromide pills[@R20] and chemical nerve gas agents,[@R10] with pesticides and pyridostigmine bromide exposures most consistently linked to GWI.[@R1] However, deployment experiences and exposures were not uniform across all troops deployed to the GW.[@R41] Some studies have used unit-level characteristics as surrogates of deployment exposures and found that illness rates in GW-deployed veterans were associated with deployment location[@R5] and time frame of deployment (ie, Operation Desert Shield, Operation Desert Storm).[@R5]

Collectively, prior studies have used several analytical techniques in separate cohorts to identify symptom prevalence rates and a common complex of symptoms in the GW-deployed population evaluated by each investigation. These analytical methods have included cluster analysis,[@R45] correlation analysis[@R13] and factor analysis.[@R3] Several studies have used meta-analytical models to examine pain, depression, psychiatric disorders, alcohol and substance use, multisymptom illness and neuropsychological performance pooled across different GW veteran populations and their controls.[@R50]

The present study is the first, to our knowledge, to pool published self-reported health symptom data from different populations of GW-deployed veterans and their controls. It uses meta-analytical statistical methods to: (1) identify symptoms reported with the highest frequency in GW-deployed veterans and their controls, (2) determine summary ORs of symptom reporting in GW-deployed veterans compared with their controls and (3) examine the differences in symptom reporting between population-based GW cohort studies and GW cohorts recruited from specific military units.

Methods {#s2}
=======

This meta-analysis was designed and conducted within the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.[@R56]

Data search {#s2a}
-----------

Two members of the research team (ALM, MKY) used the literature search strategy in [figure 1](#F1){ref-type="fig"} to identify studies examining self-reported health symptoms in deployed GW veterans and a relevant veteran comparison group. A Medline and Google Scholar database search was filtered for papers published between January 1990 and May 2017, and 'Human Subjects' and 'English' language studies (Medline search detailed in online [supplementary file](#SP1){ref-type="supplementary-material"}). References from comprehensive reports on GW literature (eg, Research Advisory Committee on Gulf War Veterans' Illnesses[@R1] and IOM[@R34]) were also reviewed. This process was performed in duplicate to ensure that all relevant, peer-reviewed GW health symptom studies were identified and reviewed for possible inclusion.
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![Meta-analysis literature search strategy (\* syntax indicates that all variations of the word was searched by the databases, eg, symptom\* searched for symptoms, symptomatology, etc). OEF/OIF, Operation Enduring Freedom/Operation Iraqi Freedom.](bmjopen-2017-016086f01){#F1}

Studies found during the literature search were included in the final analysis if the frequency of self-reported health symptoms were reported by GW-deployed veterans and a relevant veteran control group. 'GW-deployed' veterans were defined as veterans who deployed to the Gulf area in support of the 1990--1991 GW. A relevant comparison group was defined as non-deployed veterans or veterans serving in the military during the 1990--1991 GW period who deployed to areas other than the Gulf (eg, Germany, Bosnia). This group will be referred to as 'GW-era controls' throughout the rest of the manuscript. Studies were excluded if the study was conducted in theatre or during a conflict other than the GW, did not include a relevant comparison group and/or did not include self-reported health data.

The strategy used to determine the inclusion and exclusion of studies is further outlined in the four steps below ([figure 1](#F1){ref-type="fig"}):

*Step 1*: Following the literature search, study titles, abstracts and full manuscripts were reviewed for eligibility criteria using a four-step process. Exclusion criteria included the following: (1) the study population included veterans of other wars or civilians in conflict zones; (2) the study data were collected in theatre and (3) duplicate titles were found or the paper was an editorial commentary.

*Step 2*: Studies were eliminated if the study's outcome of interest was not health symptoms or health status. From step 2 forward, if it was unclear whether the study met the inclusion/exclusion criteria by reviewing the study title and abstract, full articles were reviewed.

*Step 3*: Studies were removed if the investigation: (1) had no relevant veteran comparison group; (2) was a follow-up survey to an original cohort and (3) did not include self-reported health symptoms/conditions.

*Step 4*: Studies were eliminated for (1) overlapping GW veteran populations or (2) no usable data.

Data extraction {#s2b}
---------------

When published papers were found to have used survey results from the same veteran population (eg, survey data completed by four Air Force units were published by both CDC Morbidity and Mortality Weekly Report [@R2] and Fukuda *et al*[@R4]), the prevalence data were extracted from the paper that presented results for the greatest number of self-reported health symptoms. If unique symptoms were reported in the second paper from the same veteran population, those specific symptoms were extracted from the second paper. One of the eligibility criteria for step 4 was the availability of usable data. If manuscripts published descriptive statistics other than symptom frequency (eg, mean symptom severity score, factor loading score), the corresponding author was contacted with a request for frequency data. If a follow-up request went unanswered, the study was eliminated.

The symptom checklists and wording of specific symptoms differed between studies. To determine which health symptoms matched across studies, members of the study team (ALM, PAJ, KAS, MHK) completed a qualitative comparison. For example, the Knoke *et al*[@R9] health symptom checklist includes 'chest pains' while Simmons *et al*[@R17] used 'chest pains and tightness', and a consensus was reached that these symptoms were comparable and both were included in the analysis of 'chest pain.' Once the final list of health symptoms that matched across studies was determined, the quantitative data were extracted if the symptom was reported in three or more studies. A member of the study team (ALM) extracted total n, symptomatic n, frequency, SE and unadjusted OR for both the GW-deployed veteran and GW-era veteran groups. This process was done in duplicate to assure the accuracy of the data extracted from tables in published studies. If any of the statistics listed above were not included, they were calculated using data that could be extracted.

Data analysis {#s2c}
-------------

To organise the output of the data analysis, the health symptoms were categorised into symptom domains by body system (neurological, mood cognition, sleep/fatigue, musculoskeletal, gastrointestinal, dermatological, cardiac, genitourinary, pulmonary and miscellaneous). Forest plots of one symptom from each of these categories are provided in the online [supplementary figures](#SP1){ref-type="supplementary-material"}.

For the meta-analysis of symptom prevalence in GW-deployed veterans, a random-effects binomial-normal model was used to estimate the combined log odds of a symptom and to calculate the pooled prevalence rate of individual symptoms.[@R57] The random-effects binomial-normal model accounts for the heterogeneity between studies, the binomial distribution of proportions and the normal distribution of the study-specific odds around the summary estimates (µ) with a variance term, τ.[@R2] [@R57] The starting values for µ and τ^2^ were set using the summary log odds estimate from the fixed-effects model and the variance term from the maximum likelihood random-effects model, respectively.[@R57] This process was repeated separately for the GW-era controls to yield a combined symptom prevalence in GW-era controls across studies. Next, for the meta-analysis of ORs comparing symptom reporting in GW-deployed veterans to GW-era controls, a random-effects binomial-normal model was used to estimate combined log ORs.[@R58] In the model estimating log ORs, an offset term (log n~GW-deployed~/n~GW-era\ controls~) was included to take into account different sample sizes of GW-deployed veterans and GW-era controls within a study.[@R58] The I^2^ value was calculated to assess heterogeneity between the studies used in the meta-analysis.

Confounding and bias assessment {#s2d}
-------------------------------

In a meta-analysis, study characteristics are explored as potential confounders since individual-level data are not available. In previous studies, unit-level characteristics (eg, deployment location and deployment time frame) have been used as surrogates of deployment exposures since in theatre experiences were not the same across troops deployed to the GW. Studies included in our analysis either had participants who were recruited from specific military unit cohorts or participants who were sampled from a population-based cohort of GW-deployed and GW-era controls. Using participant cohort sampling strategy as a surrogate for deployment exposures, we performed a stratified analysis to explore the effect of confounding by participant cohort sampling strategy on the symptom ORs. If the symptom was reported by three or more studies in each stratum, the summary OR was estimated for each stratum using the binomial-normal model described above.

We performed a qualitative and quantitative bias assessment. First, the studies included in the analysis were qualitatively evaluated using a hypothesis validity checklist of the 'threats to validity' outlined by Wampold *et al*[@R59] (online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The validity testing methodology was developed to critique clinical research and allows readers to evaluate: (1) hypothesis validity (eg, ambiguous or non-directional hypotheses); (2) statistical conclusion validity (eg, low statistical power or error rate problems (type I/type II error)); (3) internal validity (eg, selection bias or loss to follow-up); (4) construct validity (eg, mono-operation and mono-method bias) and (5) external validity (eg, generalisability). Each study was read and critiqued independently by two of four evaluators (ALM, MKY, AF, RG) to determine the presence or absence of specific 'threats to validity' using a multi-item checklist. Any discrepancies in the ratings were discussed before reaching a consensus final validity rating for each study. Studies were not eliminated based on the validity assessment.

Next, to assess publication and non-reporting bias on the summary ORs, we used a method described in Levy *et al*.[@R60] [@R52] For the studies that did not report an OR for a health symptom, the OR for that health symptom was assigned the null (OR=1.0) and the SE was assumed to be the same as the minimum SE among the reported studies. The summary OR was estimated using a maximum likelihood random-effects model. We could not use the binomial-normal model for the bias assessment because it relies on counts rather than ORs for the binomial level of the model and for the offset term. Although these models yield slightly different results for summary OR estimates, they provide comparable estimates of the SEs.

Results {#s3}
=======

The literature search identified 38 peer-reviewed studies examining self-reported health symptoms in GW-deployed veterans and GW-era control veterans. Sixteen of these studies were excluded because their study populations overlapped with another identified study and reported no unique health symptoms. Of the remaining papers, we extracted primary data directly from 19 of the studies. We contacted the authors of three additional papers to obtain primary data and received data for two of these studies.[@R6] We did not receive primary data for the third study, which was not included in the analysis.[@R61] [Table 1](#T1){ref-type="table"} gives an overview of the final studies used in the meta-analysis, which included data from over 129 000 GW-deployed veterans and GW-era controls from four different countries, all branches of the military, and both Active Duty and Reserve components of the military. The GW-era controls in Proctor *et al*[@R10] were deployed to Germany; all other GW-era controls were non-deployed during the period of the 1990--1991 GW. Eleven of the studies sampled participants from specific military units (eg, US Navy Seabees) and 15 were population-based studies ([table 1](#T1){ref-type="table"}).

###### 

Overview of 21 peer-reviewed studies used in health symptom meta-analysis

  Author                          Year published   GWV (n)   NGV (n)   Sampling strategy   Country     Date of collection
  ------------------------------- ---------------- --------- --------- ------------------- ----------- --------------------------------------------------------------
  CDC MMWR---Unit A\*             1995             313       364       Military unit       USA         January to March 1995
  CDC MMWR---Unit B\*             1995             119       421       Military unit       USA         January to March 1995
  CDC MMWR---Unit C\*             1995             262       581       Military unit       USA         January to March 1995
  CDC MMWR---Unit D\*             1995             470       1397      Military unit       USA         January to March 1995
  Cherry *et al*                  2001             8014      3900      Population          UK          December 1997 to September 1999
  Doebbling *et al*†              2000             1896      1799      Population          USA         September 1995 to May 1996
  Fukuda *et al*\*                1998             1163      2538      Military unit       USA         January to March 1995
  Gray *et al*                    2002             3831      3104      Military unit       USA         May 1997 to July 1999
  Iannacchione *et al*            2011             6480      1522      Population          USA         May 2007 to April 2009
  Iowa---Active Duty†             1997             985       968       Population          USA         September 1995 to May 1996
  Iowa---NG/Reserve†              1997             911       831       Population          USA         September 1995 to May 1996
  Ishøy *et al*                   1999             686       231       Population          Denmark     January 1997 to January 1998
  Kang *et al*                    2000             11 441    9476      Population          USA         November 1995 to ????
  Kelsall *et al*                 2004             1430      1533      Population          Australia   August 2000 to April 2002
  Knoke *et al*                   2000             524       935       Military unit       USA         Late 1994 to early 1995
  Murphy *et al*                  2006             149       622       Population          UK          2002 to 2003
  Nisenbaum *et al*‡              2004             3454      2577      Population          UK          November 1997 to November 1998
  Proctor *et al*§                1998             186       48        Military unit       USA         Spring 1994 to Fall 1996
  Shapiro *et al*                 2002             610       516       Population          USA         October 1998 to April 1999
  Simmons *et al*                 2004             23 358    17 730    Population          UK          August 1998 to March 2001
  Sostek *et al*                  1996             57        44        Military unit       USA         1994 to no end date mentioned but published in December 1996
  Steele                          2000             1435      409       Population          USA         February to August 1998
  Stretch *et al*---Active Duty   1995             715       1576      Military unit       USA         No mention but published in 1995
  Stretch *et al*--- Reserves     1995             766       948       Military unit       USA         No mention but published in 1995
  Unwin *et al*---Male‡           1999             3284      2408      Population          UK          August 1997 to November 1998
  Unwin *et al*--- Female‡        2002             236       192       Population          UK          August 1997 to November 1998

\*Overlapping populations, for Fukuda *et al*[@R4] only used symptoms that were not reported in CDC MMWR.[@R2]

†Overlapping populations, for Doebbling *et al*[@R3] only used symptoms that were not reported in Iowa.[@R7]

‡Overlapping populations, for Nisenbaum *et al*[@R49] only used symptoms that were not reported in Unwin *et al*.[@R18]

§NGV group for Proctor *et al*[@R10] was GW-era personnel deployed to Germany; all other control groups were non-deployed GW-era veterans.

CDC MMWR, Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report; GWV, Gulf War-deployed veterans; NG, National Guard; NGV, non-deployed Gulf War-era control veterans.

A total of 56 distinct health symptoms were reported in three or more studies and included in the meta-analysis. [Table 2](#T2){ref-type="table"} shows the pooled prevalence of each symptom in GW-deployed veterans and GW-era controls. In GW-deployed veterans, lacking energy (combined prevalence (CP): 47.0%), flatulence/burping (CP=44.6%), unrefreshing sleep (CP=42.9%), headaches (CP=42.6%) and fatigue (CP=40.8%) had the highest CP ([table 2](#T2){ref-type="table"}).

###### 

Combined prevalence of self-reported symptoms in Gulf War deployed and Gulf War-era control populations

  Self-reported symptom                            GWV frequency (%) (95% CI)   NGV frequency (%) (95% CI)
  ------------------------------------------------ ---------------------------- ----------------------------
  Lacking energy                                   47.0 (37.0 to 57.2)          27.2 (18.8 to 37.6)
  Flatulence or burping                            44.6 (32.9 to 56.9)          29.5 (17.1 to 45.9)
  Unrefreshing sleep                               42.9 (33.1 to 53.4)          21.8 (13.9 to 32.4)
  Headaches                                        42.6 (33.9 to 51.7)          23.7 (16.0 to 33.6)
  Fatigue                                          40.8 (31.4 to 45.6)          14.4 (9.0 to 22.2)
  Sinus congestion                                 40.4 (35.3 to 45.6)          24.9 (20.4 to 30.0)
  Memory problems                                  39.6 (30.8 to 49.0)          14.9 (9.3 to 22.9)
  Difficulty sleeping, falling or staying asleep   38.8 (33.4 to 44.4)          20.3 (15.5 to 26.2)
  Back pain                                        36.0 (30.1 to 42.5)          24.8 (18.1 to 33.0)
  Forgetful                                        34.8 (25.7 to 45.1)          13.7 (7.5 to 23.7)
  Joint pain                                       34.7 (29.1 to 40.8)          14.2 (11.1 to 18.0)
  Difficulty concentrating                         33.3 (27.0 to 40.3)          12.8 (9.0 to 17.9)
  Joint stiffness                                  31.2 (28.0 to 34.6)          13.4 (9.7 to 18.2)
  Irritability                                     29.9 (21.3 to 40.3)          9.2 (4.8 to 16.9)
  Itching                                          29.5 (17.9 to 44.5)          15.1 (7.8 to 27.1)
  Sleepiness                                       29.3 (18.0 to 43.8)          11.4 (5.0 to 23.6)
  Sweating                                         28.6 (16.9 to 44.0)          17.3 (9.0 to 30.6)
  Ringing in ears                                  26.6 (21.1 to 32.9)          14.8 (10.2 to 21.0)
  Recurrent headaches                              25.4 (19.8 to 31.9)          10.7 (6.3 to 17.5)
  Rash                                             24.5 (19.8 to 31.9)          7.3 (5.0 to 10.6)
  Feeling detached                                 24.0 (18.6 to 30.4)          6.6 (3.5 to 12.0)
  Muscle aches/pain                                23.0 (14.9 to 33.8)          9.5 (5.0 to 17.3)
  Trouble finding words                            22.8 (15.9 to 31.7)          8.5 (4.9 to 14.5)
  Diarrhoea/loose stools                           21.1 (15.5 to 28.0)          6.0 (4.0 to 8.8)
  Sore throat                                      20.4 (14.6 to 27.7)          10.8 (6.9 to 16.4)
  Weight gain                                      20.3 (16.4 to 24.8)          9.0 (7.5 to 10.8)
  Dizziness                                        19.5 (15.5 to 24.3)          7.9 (5.6 to 11.0)
  Coughing                                         19.2 (14.1 to 25.7)          9.1 (6.2 to 13.0)
  Numbness and tingling in body parts              18.8 (10.5 to 31.4)          8.0 (3.9 to 15.8)
  Abdominal pain and cramps                        18.7 (13.1 to 26.0)          8.1 (5.1 to 12.4)
  Wheezing                                         17.5 (9.9 to 29.2)           8.6 (4.4 to 16.1)
  Irregular heartbeat                              17.2 (7.5 to 34.8)           9.7 (3.8 to 22.7)
  Feeling depressed                                17.1 (12.7 to 22.7)          7.2 (4.1 to 12.4)
  Loss of balance/coordination                     16.9 (10.9 to 25.3)          7.3 (4.2 to 12.4)
  Bleeding gums                                    15.6 (5.5 to 37.2)           4.5 (1.1 to 16.0)
  Night sweats                                     15.5 (10.8 to 21.7)          4.2 (2.5 to 6.8)
  Chest pain                                       15.3 (7.6 to 28.1)           6.4 (3.0 to 12.9)
  Nausea                                           15.1 (11.2 to 20.1)          6.3 (3.7 to 10.3)
  Shortness of breath                              14.9 (11.2 to 19.6)          5.1 (3.2 to 7.9)
  Muscle weakness/loss of strength                 14.7 (9.8 to 21.5)           4.6 (2.7 to 7.5)
  Loss of appetite                                 14.7 (7.0 to 28.0)           4.5 (2.1 to 9.4)
  Chemical sensitivity                             14.2 (8.0 to 24.0)           6.8 (3.3 to 13.2)
  Nightmares                                       12.2 (6.3 to 22.5)           4.0 (1.5 to 10.1)
  Rapid/racing heart beat                          12.2 (7.0 to 20.4)           8.2 (7.0 to 9.5)
  Hair loss                                        11.4 (6.5 to 19.1)           3.8 (1.6 to 8.5)
  Loss of interest in sex                          11.3 (3.5 to 30.9)           4.6 (1.1 to 17.3)
  Feeling anxious/anxiety                          10.9 (5.8 to 19.6)           3.4 (1.5 to 7.5)
  Joint swelling                                   10.8 (5.8 to 19.0)           4.4 (1.9 to 9.9)
  Constipation                                     10.6 (7.6 to 14.5)           4.6 (2.7 to 7.7)
  Swollen glands                                   10.2 (5.4 to 18.5)           4.6 (2.1 to 10.1)
  Fever                                            8.8 (4.5 to 16.3)            3.6 (1.7 to 7.6)
  Vomiting                                         6.9 (4.3 to 10.7)            2.3 (0.7 to 7.4)
  Asthma                                           4.8 (3.2 to 7.1)             3.4 (2.4 to 4.9)
  Pain during intercourse                          2.6 (1.3 to 5.0)             1.6 (1.1 to 2.3)

GWV, Gulf War-deployed veterans; NGV, non-deployed Gulf War-era controls.

[Table 3](#T3){ref-type="table"} presents the results of the summary ORs of reporting symptoms in GW-deployed veterans compared with GW-era controls. GW-deployed veterans had significantly higher odds of reporting all of the analysed symptoms. The odds of reporting mood cognition (feeling detached: OR=3.59; irritability: OR=3.21), musculoskeletal (muscle weakness/loss of strength: OR=3.19), gastrointestinal (diarrhoea/loose stools: OR=3.24) and dermatological (rash: OR=3.18) symptoms were over three times higher in GW-deployed veterans compared with GW-era veterans.

###### 

Meta-analysis of self-reported health symptoms in Gulf War-deployed control compared with Gulf War-era control groups

  Full unadjusted meta-analysis results             I^2^                                                     
  ------------------------------------------------- ------ ------------------------------------------------- ------
  Neurological                                                                                               
   Tremors and/or shaking in body parts             4      2.68 (2.53 to 2.84)                               0.32
   Dizziness                                        10     2.34 (2.06 to 2.67)                               0.42
   Recurrent headache                               4      2.34 (1.74 to 3.15)                               0.94
   Numbness and tingling in body parts              8      2.32 (1.96 to 2.74)                               0.89
   Loss of balance/coordination                     3      2.18 (1.83 to 2.59)[\*](#tblfn7){ref-type="fn"}   0
   Headaches                                        18     1.78 (1.49 to 2.12)                               0.94
  Mood cognition                                                                                             
   Feeling detached                                 3      3.59 (1.83 to 7.03)[\*](#tblfn7){ref-type="fn"}   0.81
   Irritability                                     14     3.21 (2.28 to 4.52)                               0.96
   Nightmares                                       5      2.92 (1.98 to 4.30)                               0.92
   Feeling anxious/anxiety                          8      2.68 (2.10 to 3.43)                               0.91
   Memory problems                                  7      2.63 (2.10 to 3.30)                               0.91
   Trouble finding words                            7      2.62 (1.92 to 3.57)                               0.90
   Forgetful                                        6      2.52 (1.80 to 3.52)                               0.94
   Difficulty concentrating                         11     2.47 (2.06 to 2.96)                               0.89
   Feeling depressed                                14     2.26 (1.88 to 2.71)                               0.90
  Sleep, fatigue                                                                                             
   Fatigue                                          15     2.74 (2.11 to 3.57)                               0.97
   Sleepiness                                       5      2.49 (1.79 to 3.48)                               0.91
   Difficulty sleeping, falling or staying asleep   11     1.91 (1.67 to 2.19)                               0.90
   Unrefreshing sleep                               12     1.91 (1.59 to 2.30)                               0.87
   Lacking energy                                   3      1.73 (1.52 to 1.97)[\*](#tblfn7){ref-type="fn"}   0.37
  Musculoskeletal                                                                                            
   Muscle weakness/loss of strength                 5      3.19 (2.73 to 3.74)                               0.64
   Joint pain                                       17     2.36 (1.99 to 2.80)                               0.91
   Muscle aches/pain                                13     2.36 (1.91 to 2.92)                               0.94
   Joint swelling                                   3      2.35 (1.67 to 3.30)[\*](#tblfn7){ref-type="fn"}   0.92
   Joint stiffness                                  10     2.28 (1.79 to 2.90)                               0.95
   Back pain                                        9      1.47 (1.27 to 1.70)                               0.89
  Gastrointestinal                                                                                           
   Diarrhoea/loose stools                           15     3.24 (2.51 to 4.17)                               0.93
   Loss of appetite                                 5      2.58 (1.90 to 3.51)                               0.88
   Constipation                                     6      2.20 (1.77 to 2.74)                               0.83
   Nausea                                           6      2.20 (1.61 to 3.02)                               0.85
   Abdominal pain and cramps                        11     2.08 (1.79 to 2.42)                               0.68
   Vomiting                                         5      1.60 (1.45 to 1.76)[\*](#tblfn7){ref-type="fn"}   0
   Flatulence or burping                            4      1.45 (1.15 to 1.84)[\*](#tblfn7){ref-type="fn"}   0.88
  Dermatological                                                                                             
   Rash                                             14     3.18 (2.47 to 4.09)                               0.94
   Hair loss                                        9      2.60 (1.85 to 3.67)                               0.92
   Itching                                          3      1.90 (1.59 to 2.27)[\*](#tblfn7){ref-type="fn"}   0.28
   Sweating                                         3      1.67 (1.34 to 2.07)[\*](#tblfn7){ref-type="fn"}   0.87
  Cardiac                                                                                                    
   Chest pain                                       7      2.24 (1.92 to 2.61)                               0.75
   Rapid/racing heart beat                          3      2.04 (1.97 to 2.11)                               0
   Irregular heart beat                             3      1.78 (1.70 to 1.87)                               0.50
  Genitourinary                                                                                              
   Pain during intercourse                          3      2.39 (2.12 to 2.70)[\*](#tblfn7){ref-type="fn"}   0.51
   Loss of interest in sex                          5      2.34 (1.80 to 3.05)                               0.84
  Pulmonary                                                                                                  
   Shortness of breath                              6      2.81 (2.35 to 3.35)                               0.78
   Coughing                                         11     2.02 (1.72 to 2.38)                               0.88
   Wheezing                                         5      1.92 (1.66 to 2.22)                               0.71
   Sinus congestion                                 9      1.63 (1.46 to 1.81)                               0.75
   Asthma                                           7      1.38 (1.20 to 1.58)[\*](#tblfn7){ref-type="fn"}   0.47
  Miscellaneous                                                                                              
   Night sweats                                     5      3.42 (2.73 to 4.29)                               0.72
   Bleeding gums                                    4      2.99 (1.73 to 5.17)[\*](#tblfn7){ref-type="fn"}   0.94
   Fever                                            6      2.30 (1.75 to 3.03)                               0.77
   Lump in throat                                   3      2.26 (1.62 to 3.17)[\*](#tblfn7){ref-type="fn"}   0.65
   Weight gain                                      3      2.16 (1.93 to 2.41)[\*](#tblfn7){ref-type="fn"}   0
   Swollen glands                                   4      1.98 (1.68 to 2.34)[\*](#tblfn7){ref-type="fn"}   0.70
   Chemical sensitivity                             4      1.95 (1.60 to 2.38)                               0.72
   Sore throat                                      10     1.82 (1.56 to 2.12)                               0.89
   Ringing in ears                                  6      1.69 (1.42 to 2.01)                               0.78

\*OR no longer significant in bias analysis; 95% CI contains null using minimum SE.

The bias assessment demonstrated that GW-deployed veterans continued to have higher odds of reporting all the analysed symptoms compared with GW-era controls, and the majority of the ORs shown in [table 3](#T3){ref-type="table"} remained significant after assigning the missing studies an OR=1 and the minimum SE of the reported studies. However, the summary measure of effect for loss of balance/coordination, feeling detached, lacking energy, joint swelling, flatulence or burping, vomiting, itching, sweating, pain during intercourse, asthma, bleeding gums, lump in throat, swollen glands and weight gain were no longer significant (ie, 95% CI for the OR included null) when accounting for possible publication and non-reporting bias ([table 3](#T3){ref-type="table"}).

Using the 'threats to validity' checklist, the studies conducted by CDC,[@R2] Cherry *et al*,[@R15] Doebbeling *et al*,[@R3] Gray *et al*,[@R5] Simmons *et al*[@R17] and Steele[@R13] had the greatest risk for bias among the studies included in the meta-analysis. The most common 'threats to validity' among these studies were external validity (eg, generalisability) and construct validity (eg, lack of specificity for exposure and outcome measures).

In the meta-analysis stratified by sampling strategy (military-unit vs population-based studies), a total of 19 distinct health symptoms were reported in three or more studies in both strata and were included in the analysis. The results of the meta-analysis stratified by sampling strategy showed that ORs moved further from the null compared with the unadjusted meta-analysis (unadjusted results shown in [table 3](#T3){ref-type="table"}) in studies with participants recruited from specific military units, for all but 2 of the 19 analysed symptoms ([table 4](#T4){ref-type="table"}). For self-reported dizziness, irritability, fatigue and several musculoskeletal, gastrointestinal and dermatological symptoms, the adjusted OR was more than a 10% change away from the null compared with the unadjusted symptom OR ([table 4](#T4){ref-type="table"}).

###### 

Meta-analysis of self-reported health symptoms in Gulf War-deployed veterans compared with Gulf War-era controls stratified by cohort sampling strategy

  Symptom                                           Military-unit studies   Population-based studies       
  ------------------------------------------------- ----------------------- -------------------------- --- ----------------------
  Neurological                                                                                             
   Dizziness                                        3                       2.96\* (2.27 to 3.86)      7   2.21 (1.82 to 2.68)
   Headaches                                        10                      1.72 (1.44 to 2.05)        8   1.82 (1.34 to 2.47)
  Neuropsychological, psychological                                                                        
   Irritability                                     6                       3.56\* (2.48 to 5.10)      8   2.93 (1.67 to 5.14)
   Feeling depressed                                7                       2.32 (1.86 to 2.89)        7   2.22 (1.70 to 2.89)
  Sleep, fatigue                                                                                           
   Fatigue                                          8                       3.11\* (2.36 to 4.10)      8   2.33† (1.53 to 3.55)
   Difficulty sleeping, falling or staying asleep   3                       2.08 (1.71 to 2.54)        8   1.86 (1.57 to 2.19)
  Musculoskeletal                                                                                          
   Joint stiffness                                  5                       3.00\* (2.74 to 3.29)      5   1.69†(1.32 to 2.17)
   Joint pain                                       8                       2.99\* (2.49 to 3.60)      8   1.88† (1.57 to 2.24)
   Muscle aches/pain                                8                       2.87\* (2.27 to 3.63)      8   2.09† (1.59 to 2.75)
   Back pain                                        5                       1.64\* (1.32 to 2.06)      5   1.37 (1.15 to 1.63)
  Gastrointestinal                                                                                         
   Diarrhoea/loose stools                           8                       4.42\* (3.27 to 5.99)      8   2.49† (1.91 to 3.25)
   Constipation                                     3                       2.98\* (2.44 to 3.63)      3   1.79† (1.57 to 2.03)
   Abdominal pain and cramps                        5                       2.15 (1.83 to 2.52)        5   2.05 (1.66 to 2.54)
  Dermatological                                                                                           
   Rash                                             5                       3.93\* (3.18 to 4.86)      5   2.21† (1.53 to 3.20)
   Hair loss                                        6                       3.84\* (3.35 to 4.41)      6   2.20† (1.50 to 3.24)
  Cardiac                                                                                                  
   Chest pain                                       4                       2.39 (1.86 to 3.06)        4   2.06 (1.77 to 2.41)
  Pulmonary                                                                                                
   Coughing                                         5                       2.10 (1.69 to 2.61)        5   1.95 (1.54 to 2.46)
   Sinus congestion                                 3                       1.61 (1.42 to 1.82)        3   1.71 (1.34 to 2.18)
  Miscellaneous                                                                                            
   Sore throat                                      5                       2.04\* (1.71 to 2.43)      5   1.55† (1.29 to 1.86)

\*Greater than 10% change away from the null (OR=1.0).

†Greater than 10% change towards the null (OR=1.0).

Discussion {#s4}
==========

Using meta-analytical models, we combined data from 21 studies reporting on health symptoms endorsed by over 129 000 GW-deployed veterans and GW-era controls. These 21 studies represented 1990--1991 GW veterans from 18 unique veteran populations, four different countries and all branches of the military. Results of the meta-analysis showed GW-deployed veterans had increased odds of reporting all of the analysed symptoms compared with GW-era controls, indicating that the health problems associated with GW deployment include widespread, multiple body symptoms. Furthermore, the odds of GW-deployed veterans' reporting feeling detached, irritability, muscle weakness, diarrhoea and rash were more than three times higher than GW-era controls.

Additionally, in the unadjusted meta-analysis, the group of symptoms with the highest CP among GW-deployed veterans (fatigue, lacking energy, headaches and unrefreshing sleep) and the largest summary ORs comparing GW-deployed veterans to GW-era controls (irritability, feeling detached, muscle weakness, diarrhoea and rash) have been associated with objective brain imaging outcomes in recent studies,[@R62] are consistent with some of the symptoms included in GWI case definitions (CDC multisymptom illness, Kansas case definition and Haley criteria), and have been reported by GW veterans diagnosed with GWI.[@R4] Smith *et al*[@R66] recently reported that nearly half of all respondents in their population-weighted sample endorsed symptoms in all three CDC criteria categories (fatigue, mood cognition, musculoskeletal), with 96% of GWI cases reporting mood-cognition symptoms. However, we could not statistically analyse the overlap of our results with symptoms identified in current GWI case definitions because of a lack of individual symptom data.

We also characterised studies based on their cohort sampling strategy and performed a stratified meta-analysis comparing population-based studies to military unit-based studies, using military unit as a surrogate for deployment exposures. The stratified analysis showed evidence of confounding by sampling strategy. In studies where participants were sampled from specific military units, the adjusted summary ORs were higher compared with the unadjusted summary ORs. These results agree with previous studies that found GW veteran health problems were associated with deployment/operational time frame[@R5] and location[@R5] and may be reflective of specific deployment exposures experienced by different military units in the GW theatre.[@R36]

In our stratified analysis, several of the symptoms with higher adjusted ORs in the military-unit cohort studies have been associated with GW exposures in previous research. For example, in the Fort Devens cohort, Proctor *et al*[@R10] found that musculoskeletal symptom reporting was associated with pesticide and chemical warfare agent exposure, while neurological and psychological symptoms were linked to self-reported exposure to debris from SCUDS and chemical warfare agents. Similarly, McCauley *et al*[@R67] found that self-reported exposure to chemical warfare agents was associated with fatigue and gastrointestinal symptoms, and Cherry *et al*[@R68] found that self-reported exposure to pesticides was related to neurological, dermatological and musculoskeletal symptoms. Using the Kansas case definition of GWI, GW veterans with self-reported exposure to pesticides and pyridostigmine bromide pills were more likely to meet GWI case criteria compared with unexposed GW veterans.[@R37] In addition, Iannacchione *et al*[@R6] reported that GW veterans who served as air flight crew or Army Special Forces during the war were 10 times more likely to meet criteria for GWI, as defined by the Haley syndrome criteria.

A major strength of this meta-analysis is the method used to estimate the summary measures of effect. The binomial-normal model is recommended for rare events, which made the analysis of some of the lesser reported health symptoms more robust. Moreover, the binomial-normal model is designed to analyse binary outcomes and take into account the non-normal (eg, binomial) distribution of the prevalence and OR effect estimate, in contrast to the fixed-effects or maximum likelihood random-effects model, which assumes normal distributions of effect estimates and is the traditional meta-analytical approach.

As mentioned previously, a limitation of a meta-analysis is the lack of individual-level data. Consequently, we were not able to assess the effect of some covariates relevant to health symptom reporting (eg, post-traumatic stress disorder and specific deployment exposures). While some of the primary studies published adjusted ORs,[@R5] these effect measures were not adjusted for the same covariates across all studies. This limits comparability of the combined study data and increases the heterogeneity across studies; therefore, we extracted or calculated unadjusted ORs in this meta-analysis. In a meta-analysis, analysing study-level covariates controls for some heterogeneity across studies caused by differences in study methods and increases the confidence in the summary measure of effect.

The stratified analysis, examining sampling strategy (population-based cohorts vs military-unit cohorts) as a surrogate for differences in deployment experiences in specific military units compared with the entire GW-deployed population, also had its limitations. We recognise that within each strata deployment experiences could still vary; however, we could not examine any associations with specific exposures because of a lack of individual or unit-level exposure data. Furthermore, increased symptom reporting in military-unit studies compared with population-based studies could be due to differences other than deployment exposures (ie, more selective population, different predeployment training) between the study populations. There were other study characteristics such as country of origin or data collection time frame (ie, number of years postdeployment) that could affect symptom reporting which were unaccounted for in this meta-analysis.

Another limitation of the meta-analytical approach is the effect of publication and non-reporting bias on results. Publication bias occurs when studies with positive findings are more likely to be published than studies with null and/or negative findings. Non-reporting bias occurs when studies fail to publish non-significant results. In this analysis, we were limited to peer reviewed, published literature on GWI and then further limited by the number of health symptoms included in study questionnaires and reported by each study. To address the latter issue, we performed a bias analysis where individual study ORs were assigned the null value for a symptom that was unreported. The meta-analysis was rerun with the null ORs, and 42 out of the 56 summary ORs remained significant ([table 3](#T3){ref-type="table"}), demonstrating that the significant associations between GW veteran status and self-reported health symptoms cannot be attributed solely to publication bias.

Conclusion {#s5}
==========

Results of this meta-analysis of 21 health symptom studies provide the first comprehensive reference of pooled health symptom data from 129 000 deployed GW and GW-era control veterans representing four different countries and all branches of the military. The increased odds of symptom reporting among GW-deployed veterans compared with GW-era controls, for symptoms related to mood cognition, fatigue, musculoskeletal, gastrointestinal and dermatological symptom categories suggests these symptoms should continue to be used in symptom surveys when assessing GW veterans for health status, illness biomarkers or treatment trial efficacy.[@R1] The stratified analysis demonstrates important differences by study sampling strategy, with higher symptoms ORs in studies of specific military-unit cohorts, potentially reflecting symptoms that are associated with specific deployment-related exposures that warrant further study.
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